536 related articles for article (PubMed ID: 27034984)
1. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
3. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
4. Pediatric high-grade glioma: biologically and clinically in need of new thinking.
Jones C; Karajannis MA; Jones DTW; Kieran MW; Monje M; Baker SJ; Becher OJ; Cho YJ; Gupta N; Hawkins C; Hargrave D; Haas-Kogan DA; Jabado N; Li XN; Mueller S; Nicolaides T; Packer RJ; Persson AI; Phillips JJ; Simonds EF; Stafford JM; Tang Y; Pfister SM; Weiss WA
Neuro Oncol; 2017 Feb; 19(2):153-161. PubMed ID: 27282398
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
Maleszewska M; Kaminska B
Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
[TBL] [Abstract][Full Text] [Related]
6. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
7. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
[TBL] [Abstract][Full Text] [Related]
8. High frequency of H3F3A (K27M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord.
Gessi M; Gielen GH; Dreschmann V; Waha A; Pietsch T
Acta Neuropathol; 2015 Sep; 130(3):435-7. PubMed ID: 26231952
[No Abstract] [Full Text] [Related]
9. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
10. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
11. [Aberrant expression of sox2 gene in malignant gliomas].
Volnitskiĭ AV; Semenova EV; Shtam TA; Kovalev RA; Filatov MV
Tsitologiia; 2014; 56(7):504-10. PubMed ID: 25696994
[TBL] [Abstract][Full Text] [Related]
12. Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.
Krug B; De Jay N; Harutyunyan AS; Deshmukh S; Marchione DM; Guilhamon P; Bertrand KC; Mikael LG; McConechy MK; Chen CCL; Khazaei S; Koncar RF; Agnihotri S; Faury D; Ellezam B; Weil AG; Ursini-Siegel J; De Carvalho DD; Dirks PB; Lewis PW; Salomoni P; Lupien M; Arrowsmith C; Lasko PF; Garcia BA; Kleinman CL; Jabado N; Mack SC
Cancer Cell; 2019 May; 35(5):782-797.e8. PubMed ID: 31085178
[TBL] [Abstract][Full Text] [Related]
13. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
[TBL] [Abstract][Full Text] [Related]
14. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
Chen CCL; Deshmukh S; Jessa S; Hadjadj D; Lisi V; Andrade AF; Faury D; Jawhar W; Dali R; Suzuki H; Pathania M; A D; Dubois F; Woodward E; Hébert S; Coutelier M; Karamchandani J; Albrecht S; Brandner S; De Jay N; Gayden T; Bajic A; Harutyunyan AS; Marchione DM; Mikael LG; Juretic N; Zeinieh M; Russo C; Maestro N; Bassenden AV; Hauser P; Virga J; Bognar L; Klekner A; Zapotocky M; Vicha A; Krskova L; Vanova K; Zamecnik J; Sumerauer D; Ekert PG; Ziegler DS; Ellezam B; Filbin MG; Blanchette M; Hansford JR; Khuong-Quang DA; Berghuis AM; Weil AG; Garcia BA; Garzia L; Mack SC; Beroukhim R; Ligon KL; Taylor MD; Bandopadhayay P; Kramm C; Pfister SM; Korshunov A; Sturm D; Jones DTW; Salomoni P; Kleinman CL; Jabado N
Cell; 2020 Dec; 183(6):1617-1633.e22. PubMed ID: 33259802
[TBL] [Abstract][Full Text] [Related]
15. H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
Furth N; Algranati D; Dassa B; Beresh O; Fedyuk V; Morris N; Kasper LH; Jones D; Monje M; Baker SJ; Shema E
Cell Rep; 2022 May; 39(7):110836. PubMed ID: 35584667
[TBL] [Abstract][Full Text] [Related]
16. Preclinical therapeutic targets in diffuse midline glioma.
Meel MH; Kaspers GJL; Hulleman E
Drug Resist Updat; 2019 May; 44():15-25. PubMed ID: 31202081
[TBL] [Abstract][Full Text] [Related]
17. Molecular Basis of Pediatric Brain Tumors.
Klonou A; Piperi C; Gargalionis AN; Papavassiliou AG
Neuromolecular Med; 2017 Sep; 19(2-3):256-270. PubMed ID: 28748347
[TBL] [Abstract][Full Text] [Related]
18. Pediatric gliomas as neurodevelopmental disorders.
Baker SJ; Ellison DW; Gutmann DH
Glia; 2016 Jun; 64(6):879-95. PubMed ID: 26638183
[TBL] [Abstract][Full Text] [Related]
19. Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy.
Graham MS; Mellinghoff IK
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003625
[TBL] [Abstract][Full Text] [Related]
20. Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.
Vanan MI; Underhill DA; Eisenstat DD
Neurotherapeutics; 2017 Apr; 14(2):274-283. PubMed ID: 28233220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
